



## Patient Referral Process

- Referral Received**  
MDO sends orders, demos, labs, clinics, etc.
- Benefits Verified**  
Intake reviews info, verify benefits (INN/OON/self-pay).
- Communication**  
Contact patient with updates and MDO.
- Prior Authorization**  
Submit PA, if needed.
- Co-pay**  
Inform Patient of copay assistance enrollment and collect copay, if any.
- Prescription Filled**  
Pharmacy scheduled delivery or pick-up.

Home infusion necessitates nursing and pharmacy services coordinated by home infusion or specialty pharmacy providers.



Nurses visit the patient's home to administer and monitor the therapy.



Between visits, nurses and pharmacists provide patient education, care planning, care coordination, and care management.



### Infusion Suite

12144 Dairy Ashford Rd,  
Suite 100, Sugar Land,  
Tx 77478

Phone: **(832)939-8137**

Toll Free: **(877)993-3548**

Fax: **(832)939-8128**

### Required tests for autoimmune diseases

<b>CIDP</b>	EMG/NCS, disease onset, CSF results, nerve biopsy (if done)
<b>GBS</b>	EMG/NCS, disease onset
<b>MG</b>	Current medications, medications tried and failed, antibody results, current symptoms
<b>MMN</b>	EMG/NCS, antibody results
<b>MS</b>	Diagnosis of relapsing-remitting MS, current medications, medications tried and failed
<b>Myositis</b>	EMG/NCS, muscle biopsy, lab results for muscle enzymes such as CK or aldolase, antibody results, current medications, medications tried and failed
<b>SPS</b>	EMG/NCS, anti-GAD antibody results, current medications, medications tried and failed



SCAN  
To Learn more





## ICD Coding Guide

Medicare Part B covered code for Hizentra provided in the home setting

Select the most appropriate ICD-10-CM code that corresponds to the patient's conditions

<b>G25.82</b>	Stiff-man syndrome
<b>G35</b>	Multiple sclerosis
<b>G36.0</b>	Neuromyelitis optica [Devic]
<b>G61.0</b>	Guillain-Barré syndrome
<b>G61.81</b>	Chronic Inflammatory demyelinating polyneuritis
<b>G61.82</b>	Multifocal motor neuropathy
<b>G62.89</b>	Other specified polyneuropathies
<b>G70.00</b>	Myasthenia gravis without (acute) exacerbation
<b>G70.01</b>	Myasthenia gravis with (acute) exacerbation
<b>G70.80</b>	Lambert-Eaton syndrome, unspecified
<b>G70.81</b>	Lambert-Eaton syndrome in disease classified elsewhere
<b>G72.2</b>	Myopathy due to other toxic agents
<b>G72.81</b>	Critical illness myopathy
<b>G72.89</b>	Other specified myopathies
<b>G73.1</b>	Lambert-Eaton syndrome in neoplastic disease
<b>G73.3</b>	Myasthenic syndromes in other diseases classified elsewhere
<b>G73.7</b>	Myopathy in diseases classified elsewhere
<b>M32.9</b>	Systemic lupus erythematosus, unspecified
<b>M33.10</b>	Other dermatopolymyositis, organ involvement unspecified
<b>M33.12</b>	Other dermatopolymyositis with myopathy
<b>M33.20</b>	Polymyositis, organ involvement unspecified
<b>M33.22</b>	Polymyositis with myopathy
<b>M33.90</b>	Dermatopolymyositis, unspecified, organ involvement unspecified
<b>M33.91</b>	Dermatopolymyositis, unspecified with respiratory involvement
<b>M33.92</b>	Dermatopolymyositis, unspecified with myopathy
<b>M33.99</b>	Dermatopolymyositis, unspecified with other organ involvement